retatrutide clinical trial results 2024 Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the Phase III retatrutide study demonstrates
Pay in 4 interest-free payments of $5.02 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1



:max_bytes(150000):strip_icc()/nasal-spray-GettyImages-1307364119-342cadbe116d4cc7b773e3869d833779.jpg)


















